Search Results - Fanny Le Du

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study

    Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study by Charlotte Bellier, Laurence Gladieff, Fanny Le Du, Dominique Berton, Charlotte Bonnard, Delphine Suau, Anne-Céline Richard, Ophélie Brenner, Amir Lahouegue, Gilles Freyer, Anne Floquet, Sophie Frank, Maria Kfoury

    Published 2023-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients

    Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients by Julien Corné, Fanny Le Du, Véronique Quillien, Florence Godey, Lucie Robert, Héloïse Bourien, Angélique Brunot, Laurence Crouzet, Christophe Perrin, Claudia Lefeuvre-Plesse, Véronique Diéras, Thibault De la Motte Rouge

    Published 2021-08-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.

    EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer tre... by Fanny Le Du, Takeo Fujii, Kumiko Kida, Darren W Davis, Minjeong Park, Diane D Liu, Weiguo Wu, Mariana Chavez-MacGregor, Carlos H Barcenas, Vicente Valero, Debu Tripathy, James M Reuben, Naoto T Ueno

    Published 2020-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

    Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow... by Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Fanny Le Du, Pierre-François Dupré, Thomas Bachelot, Philippe Gabelle, Marie-Pierre Chauvet, David Coeffic, Catherine Barbe, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Abdennour Ferhat, Julien Dupin, Alina Berriolo-Riedinger, Laurent Arnould

    Published 2020-11-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

    Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. by Celine Lefebvre, Thomas Bachelot, Thomas Filleron, Marion Pedrero, Mario Campone, Jean-Charles Soria, Christophe Massard, Christelle Lévy, Monica Arnedos, Magali Lacroix-Triki, Julie Garrabey, Yannick Boursin, Marc Deloger, Yu Fu, Frédéric Commo, Véronique Scott, Ludovic Lacroix, Maria Vittoria Dieci, Maud Kamal, Véronique Diéras, Anthony Gonçalves, Jean-Marc Ferrerro, Gilles Romieu, Laurence Vanlemmens, Marie-Ange Mouret Reynier, Jean-Christophe Théry, Fanny Le Du, Séverine Guiu, Florence Dalenc, Gilles Clapisson, Hervé Bonnefoi, Marta Jimenez, Christophe Le Tourneau, Fabrice André

    Published 2016-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: